Talk to the analystsTalk to us
Language: EN
Talk to the analysts

Sirnaomics

HKEX: 2257

A clinical-stage biotechnology company developing RNAi medicines.

RNAi medicines stop a disease-causing gene from making its protein.

Company
Sirnaomics Ltd.
Sector
Biotechnology
First report

Why Sirnaomics stands out

  • Medicine that reaches beyond the liver.

    Approved siRNA medicines work almost entirely in the liver. Its PNP platform has been tested in patients outside it.

  • The dosing interval, by design.

    Its GalAhead platform is built to set how long a dose lasts: about three months for one candidate, about twelve for another.

  • Tested in patients.

    In 99 skin cancer patients, the company reports no drug-related side effects elsewhere in the body.

  • Its pipeline is its own.

    Sirnaomics holds the worldwide rights to its five lead programmes.

From the company’s reports and our research.

Company, platforms and pipeline

Pressing Play loads the video from YouTube: Google receives your IP address, also in the USA, and may store data on your device. Privacy policy

Share price

Pressing the button loads the chart from Stockdio in the USA: Stockdio receives your IP address and may store data on your device. The USA offers no EU-level data protection here, and US authorities could access the data. Privacy policy

Hong Kong Stock Exchange, HKD, Chart: Stockdio

Research on Sirnaomics

  1. Fourth quarter 2026

  2. Update

    The RNAimmune money is in, and the FDA has answered in writing on STP705 (PDF, opens in a new tab)

    Eight questions to start

    1. What did Sirnaomics announce to the Hong Kong exchange on 6 October about RNAimmune, and what does the state-owned fund now hold?
    2. After the deal, who owns what in RNAimmune Inc. and its Guangzhou subsidiary, and what is Sirnaomics' indirect share?
    3. Which two milestones does the RNAimmune agreement set for the Guangzhou subsidiary, and by when?
    4. What did the FDA say in its written responses of 10 September about the next study of STP705?
    5. How is the four-arm Phase 2b study of STP705 designed, and what does each arm compare?
    6. Which two gene-silencing molecules make up STP705, and what does each one silence?
    7. How does the report build its 30.5% chance of approval for STP705 from three probabilities?
    8. Which items did the report follow since 7 September, and where does each one stand now?

    Open it in your own AI

    Download the PDF

    Update, 13 pages

  3. Third quarter 2026

  4. Initiation

    Every approved siRNA drug works in the liver. This one was injected into skin cancer (PDF, opens in a new tab)

    Eight questions to start

    1. In three sentences: what does Sirnaomics develop, and what sets its PNP and GalAhead delivery platforms apart?
    2. How does the report describe Sirnaomics' funding plans after the cost reset? Explain the cash, the yearly spending rate and the placement it assumes.
    3. How would Sirnaomics earn money from its drugs? Explain the upfronts, milestones and royalties the report assumes from partners.
    4. What is the timeline for STP705 in skin cancer, from the FDA roadmap and a partner signing to the pivotal studies and launch?
    5. Which partners has Sirnaomics signed so far, and what do the Walvax and ChemPartner agreements cover?
    6. How did Sirnaomics change its strategy in the 2026 half year, and which programmes will it now advance through partners?
    7. Which events does the report say to watch, from a first partnership to the STP705 pivotal start, and what would each one show?
    8. What have the human trials of STP705, STP707 and STP122G shown so far, and which data does the report say are still to be published?

    Open it in your own AI

    Download the PDF

    Initiation, 36 pages

Research, not investment advice. Every report carries its full disclosures. Research disclosures

We stay.

Results, a deal, a contract, new guidance: when it moves the case, you get our view.

All research